INS and metabolic disease: However, since the 2000s, 28 new non-insulin peptide drugs have been approved worldwide, and more than 80 new peptide drugs from other research areas, mainly metabolic disease, and oncology (Lau and Dunn 2018), and more than 170 peptides, are in active clinical development (Henninot et al. 2018; Lau and Dunn 2018).